Autism spectrum disorder (commonly known as autism) is a complex and prevalent neurodevelopmental condition characterized by challenges in social behavior, restricted interests, and repetitive behaviors. It is projected that the annual cost of autism spectrum disorder in the US will reach USD 461 billion by 2025. However, despite being a major public health problem, effective treatment for the underlying symptoms remains elusive. As numerous literature data indicate the role of gut microbiota in autism prognosis, particularly in terms of alleviating gastrointestinal (GI) symptoms, high hopes have been placed on probiotics for autism treatment. Approximately twenty clinical studies have been conducted using single or mixed probiotic cultures. However, unequivocal results on the effect of probiotics on people with autism have not been obtained. The small sample sizes, differences in age of participants, choice of probiotics, dose and duration of treatment, outcome measures, and analytical methods used are largely inconsistent, making it challenging to draw distinctive conclusions. Here, we discuss the experimental evidence for specific gut bacteria and their metabolites and how they affect autism in light of the phenotypic and etiological complexity and heterogeneity. We propose a personalized medicine approach for using probiotics to increase the quality of life of individuals with autism by selecting specific probiotics to improve particular features of the condition.
Background: Antibiotic-associated gut dysbiosis affects lung health and contributes to disease progression, but the individual response to antibiotics, which leads to host-specific reactions to the same respiratory insult, is not fully understood. Methods: Before infection with Aspergillus fumigatus, Albino Oxford (AO) and Dark Agouti (DA) rats received a mixture of antibiotics with poor systemic absorption to induce microbial perturbation only in the gut, and lung and gut tissue and colonic contents were analyzed. Results: Treatment with antibiotics induced gut inflammation in both rat strains, which was more pronounced in AO rats, and a disturbance in lung immunity was observed only in DA rats. Antibiotic-associated gut microbiota disturbance revealed rat strain-specific bacterial profiles (increased Gammaproteobacteria in DA and decreased Coriobacteriia in AO rats). Although gut dysbiosis increased the risk of lung A. fumigatus infection in both rat strains, a higher fungal burden was detected in the lungs of AO rats, whereas lymph node cell activation and lung tissue inflammation were observed in DA rats. Conclusions: Rat strain differences in response to antibiotic- and/or infection-induced gut dysbiosis suggest that basal gut microbiota may influence the lung immune response during A. fumigatus disease, highlighting the importance of the interplay of genotype-specific host gut microbial community with the environmental constraints in shaping individual immune makeup.